Cancer Biomarkers Market

The Global Cancer Biomarkers Market, which was valued at $12.4 billion in 2021, is expected to reach $28.2 billion by 2030, with a compound annual growth rate (CAGR) of 16.6% from 2023 to 2030. A recent research study examines various factors impacting the industry, including trends, pricing, patents, conferences and webinars, key stakeholders, and purchasing behavior. The market's expansion is primarily driven by the increased utilization of cancer biomarkers in drug discovery and development, ongoing research on cancer biomarkers, technological advancements, and the growing global incidence of cancer.

Market Dynamics of the Cancer Biomarkers Market:
Advancing Technology as a Growth Driver:
Technological advancements in array and proteomics technologies have effectively addressed challenges related to the identification and understanding of proteins, including their functions and interactions. These advancements have simplified the process of discovering and developing new cancer biomarkers.

Opportunity: Personalized medicine
Personalized medicine aims to identify the most suitable treatment options for individual patients, and cancer biomarkers play a vital role in this approach. Consumables used in cancer biomarker testing enable the detection of diseases, and cancer biomarker diagnostic products serve as companion diagnostics for investigational therapies. As a result, the field of personalized medicine offers significant growth opportunities for market participants.

Restraint: Technical Challenges in Sample Collection and Storage
Service providers face significant challenges in sample collection, followed by ensuring the accessibility and optimal storage conditions for these samples. Strict quality control measures are necessary, and different samples are required for risk detection, screening, diagnosis, and monitoring processes.

Challenge: Validating Cancer Biomarkers
Validating cancer biomarkers involves evaluating assays and measuring performance characteristics such as sensitivity, specificity, and reproducibility. This validation process is crucial to establish cancer biomarkers as reliable tools for supporting drug development, medical care, and investment decisions in the biopharmaceutical industry.

The protein biomarkers segment holds the largest share in the cancer biomarkers market, reflecting the extensive research dedicated to cancer biomarkers.
Among different cancer types, breast cancer is the leading segment in the cancer biomarkers market due to the increasing global incidence of this disease.
Omics technologies, such as genomics and proteomics, dominate the cancer biomarkers market in terms of profiling technologies. This growth is driven by the expanding use of cancer biomarkers in innovative developments and advancements.

Diagnostics segment accounted for the largest share in the cancer biomarkers market, by application

The cancer biomarkers market encompasses various applications, including diagnostics, research and development, prognostics, risk assessment, and others. Among these, the diagnostics segment holds the largest market share. The increasing utilization of cancer biomarkers for companion diagnostics is anticipated to propel market growth.

In terms of regional markets, North America emerges as the dominant player in the cancer biomarkers market. The global market is segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America accounted for the largest share of the global market. This growth can be attributed to the region's growing population, which correlates with heightened research activities and advancements in the field of cancer biomarkers.

Please note that the information provided is based on assumptions of accuracy and is up to date as of my knowledge cutoff in September 2021.
• F. Hoffmann-LA Roche Ltd.( (Switzerland)
• Thermo Fisher Scientific, Inc. (US)
• Qiagen N.V. (Netherlands)
• Bio-Rad Laboratories (US)
• Illumina (US)

Future Revenue Growth Dynamics
This report categorizes the cancer biomarkers market to forecast revenue and analyze trends in each of the following submarkets:

By Biomarkers Type
• Protein Biomarkers
• Genetic Biomarkers
• Other Cancer Biomarkers

By Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Non-Hodgkin's Lymphoma
• Kidney Cancer
• Other Cancer Types

By Profiling Technologies
• Omics Technologies
• Imaging Technologies
• Immunoassay
• Bioinformatics
• Cytogenetics

By Application
• Diagnostics
• Research & Development
• Prognostics
• Risk Assessment
• Other Applications

By Region
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia and New Zealand
o Rest of Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments
• F. Hoffmann-La Roche Ltd. (Switzerland) introduced the Elecsys Anti-p53 immunoassay in April 2021, aimed at assisting in the diagnosis of various types of cancer.
• Thermo Fisher Scientific (US) obtained FDA approval in December 2020 for its NGS-based companion diagnostic designed for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
• Qiagen N.V. (Netherlands) launched the therascreen BRAF test in April 2020 as a companion diagnostic for a BRAFTOVI (encorafenib)-based treatment regimen for metastatic colorectal cancer.